New drug protocol for Nymox prostate drug
The FDA has accepted the new clinical trial protocol for Nymox Pharmaceutical's investigational new drug NX-1207 for benign prostatic hyperplasia (BPH). The company will be proceeding into pivotal US Phase II testing of NX-1207.
The FDA has accepted the new clinical trial protocol for Nymox Pharmaceutical's investigational new drug NX-1207 for benign prostatic hyperplasia (BPH). The company will be proceeding into pivotal US Phase II testing of NX-1207.
'We are extremely pleased that the new protocol is approved,' said Dr Paul Averback, ceo of Nymox.
'Nymox is very optimistic about the prospects for NX-1207. We plan to move ahead as expeditiously as possible.'
Nymox recently reported on favourable results from Phase I and Phase I-II testing of NX-1207. The drug led to statistically significant clinical improvement, with statistically significant prostate shrinkage in the completed trials. There was no clinically significant toxicity from NX-1207 in the trials thus far.
BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.